The European Medicines Agency (EMA) authorized this Friday a new technique for injecting the vaccine against monkeypox, which will make it possible to immunize more people and thus prevent a possible shortage.
European countries can now administer the Imvanex vaccine just under the upper layer of the skin (intradermally) and no longer deep (subcutaneously) as is currently the case, and thus only use a fifth of the dose, the EMA said in a statement.
This technique which uses a lower dose of vaccine produces the same immunity with an equivalent level of antibodies as the other method, but the risk of skin irritation is higher, the Amsterdam-based watchdog has warned .
"National authorities may decide, as a temporary measure, to use Imvanex by intradermal injection at a lower dose to protect those at risk during the current outbreak of monkeypox, as long as the vaccine supply remains limited,” the EMA said.
European Commissioner Stella Kyriakides stressed that this authorization was an “extremely important decision because it makes it possible to vaccinate five times more people with the stocks of vaccines that we currently have”.
“This ensures better access to vaccination for people at risk and healthcare professionals,” she added in a statement.
Health
Monkeypox: “Zero Monkeypox” objective, but vaccination considered too slow… Can we avoid the pandemic?
Health
Monkeypox: WHO calls for vigilance after contamination of a dog
Vaccine
monkey pox
Health